TL/DR –
The U.S. health care system spent 18.3% of its GDP in 2021, a larger percentage than other developed countries, but remains unaffordable for a significant portion of Americans. Despite federal spending of $1.5 trillion in 2022 to support Medicare and Medicaid, political influence, corporate profit motives, and high spending on lobbying by health care corporations perpetuate an unsustainable disparity in health care costs. However, significant reforms such as the Affordable Care Act (ACA) and the Biden administration’s Inflation Reduction Act of 2022 have had a positive impact on individual health coverage and drug prices, though these reforms are continually threatened by corporate interests prioritizing profit.
Understanding the U.S. Health Care System Paradox and the Need for Reform
In 2021, health care spending in the U.S. accounted for 18.3% of the GDP, in contrast to the 8.8% to 12.8% of GDP in other developed countries. Yet, health care remains unaffordable for many Americans despite the substantial government subsidies.
The U.S. government spent $1.5 trillion in 2022 on Medicare and Medicaid alone, covering over 135 million Americans. Additionally, the Affordable Care Act provides billions in subsidies to make private insurance more affordable. Despite this support, health care costs continue to rise due to corporate profit motives.
Health care corporations spent over $700 million on lobbying in 2022. These corporations aim to maintain the status quo, making it challenging for elected officials to push for meaningful health care reform.
However, significant health care reforms have been achieved, such as the Affordable Care Act (ACA). The ACA provided protection for individuals with preexisting conditions, benefiting an estimated 133 million Americans. It also expanded Medicaid, offering health coverage to more than 24.5 million low-income Americans.
The Biden administration has also made strides in reducing drug prices, capping insulin prices at $35 per month for Medicare recipients, which provided relief for nearly 3.3 million seniors. Unfortunately, these reforms are under constant threat from pharmaceutical companies fighting back against efforts to lower drug prices. They maintain that price controls will stifle innovation, despite evidence to the contrary from countries such as Germany and Switzerland.
The U.S. health care system currently prioritizes corporate profits over patient needs, with political influences from health insurance providers hindering meaningful reform. Electing leaders who prioritize the welfare of the people over corporate interests can lead to significant change. The needs of patients must take precedence over corporate profits for true reform to occur.
Related Articles
—
Read More Health & Wellness News ; US News